top of page

What is cbd?

CBD (cannabidiol) is a fascinating compound derived from the hemp plant, with roots dating back to ancient times. Hemp, one of the earliest agricultural crops known to humanity, traces its history back to 8000 BCE in regions that are now part of modern-day China and Taiwan.

Early remnants of hemp include the discovery of hemp cords used in pottery and records indicating that hemp seeds and oil were staples in Chinese cuisine. As agriculture began to take shape around 10,000 years ago, hemp was among the first crops cultivated by our ancestors.

In recent years, CBD has captured the attention of the scientific community like never before, leading to a surge in research and exploration.

At Lordan Labs, while we refrain from making specific medical claims about our products, we eagerly follow the latest scientific investigations into the potential benefits of CBD, as well as other cannabinoids such as CBG, CBN, CBDa, and CBGa.

Research studies have delved into a wide range of potential applications for these compounds, including their effectiveness in addressing conditions such as epilepsy, anxiety, arthritis, stress reduction, sleep disorders, inflammation, chronic pain, depression, autism, certain cancers, and even their role in slowing the aging process in brain cells. The breadth of ongoing research on CBD and hemp is continually expanding, offering a glimpse into the vast potential this remarkable plant has to offer humanity.

As we venture deeper into this exciting realm of scientific exploration, it's evident that we are only beginning to unlock the myriad benefits that CBD and hemp-derived compounds can provide. We invite you to explore the links below for more information on current CBD research, and please don't hesitate to reach out to us with any questions you may have. Together, we can continue to uncover the many ways in which CBD and hemp can contribute to a healthier and more vibrant future. Check out some of the studies below, and please reach out with any questions!

  • Cannabis Drug Shows Promise in Treating Schizophrenia


  • Cannabidiol, a Cannabis Sativa Constituent, as an Antipsychotic Drug


  • Cannabidiol as a Potential Treatment for Psychosis


  • Medical use of Cannabis. Cannabidiol: a New Light for Schizophrenia?


  • Cannabinoids and Schizophrenia: Therapeutic Prospects


  • Cannabidiol Monotherapy for Treatment-Resistant Schizophrenia


  • Marijuana Compound Treats Schizophrenia with Fewer Side Effects: Clinical Trial


  • Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model


  • Cannabidiol Enhances Anandamide Signaling and Alleviates Psychotic Symptoms of Schizophrenia


  • A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of Translational Investigation


  • Cannabis with High Cannabidiol Content is Associated with Fewer Psychotic Experiences


  • Neuronal and Molecular Effects of Cannabidiol on the Mesolimbic Dopamine System: Implications for Novel Schizophrenia Treatments


  • Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal Studies


  • Clearing the Smoke: What do We Know About Adolescent Cannabis Use and Schizophrenia?


  • Peripheral Endocannabinoid System Dysregulation in First-episode Psychosis


  • Study: Cannabidiol Holds Promise for Treating Psychosis


  • The Yin and Yang of Cannabis-induced Psychosis: the Actions of Delta9-Tetrahydrocannabinol and Cannabidiol in Rodent Models of Schizophrenia


  • Potential Protective Effects of Cannabidiol on Neuroanatomical Alterations in Cannabis Users and Psychosis: a Critical Review


  • Inhibition of Colon Carcinogenesis by a Standardized Cannabis Sativa Extract With High Content of Cannabidiol


  • Cannabidiol, a Non-psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells Through a Multitarget Effect


  • Gamma-irradiation Enhances Apoptosis Induced by Cannabidiol, a Non-psychotropic Cannabinoid, in Cultured Hl-60 Myeloblastic Leukemia Cells


  • Cannabidiol as a Novel Inhibitor of Id-1 Gene Expression in Aggressive Breast Cancer Cells


  • Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy


  • Cannabinoids for Cancer Treatment: Progress and Promise


  • Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma


  • Cannabidiol Inhibits Growth and Induces Programmed Cell Death in Kaposi Sarcoma-associated Herpesvirus-infected Endothelium


  • Cannabidiol-Induced Apoptosis in Human Leukemia Cells: A Novel Role of Cannabidiol in the Regulation of p22phox and Nox4 Expression


  • Triggering of the Trpv2 Channel by Cannabidiol Sensitizes Glioblastoma Cells to Cytotoxic Chemotherapeutic Agents


  • Cannabis and Cannabinoids (PDQ®)–Health Professional Version


  • Cannabidiol as Potential Anticancer Drug


  • A Comparative Study on Cannabidiol-induced Apoptosis in Murine Thymocytes and El-4 Thymoma Cells


  • Cannabidiol-induced Apoptosis in Human Leukemia Cells: a Novel Role of Cannabidiol in the Regulation of P22phox and Nox4 Expression


  • Cannabidiol Inhibits Lung Cancer Cell Invasion and Metastasis Via Intercellular Adhesion Molecule-1


  • Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy, Safety, and Tolerability of Thc:cbd Extract and Thc Extract in Patients With Intractable Cancer-related Pain


  • Induction of Apoptosis by Cannabinoids in Prostate and Colon Cancer Cells Is Phosphatase Dependent


  • Anticancer Activity of Anandamide in Human Cutaneous Melanoma Cells


  • Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress


  • Therapeutic Potential of Cannabinoid-based Drugs


  • Oral Anti-inflammatory Activity of Cannabidiol, a Non-psychoactive Constituent of Cannabis, in Acute Carrageenan-induced Inflammation in the Rat Paw


  • The Abnormal Cannabidiol Analogue O-1602 Reduces Nociception in a Rat Model of Acute Arthritis Via the Putative Cannabinoid Receptor GPR55


  • Preliminary Assessment of the Efficacy, Tolerability and Safety of a Cannabis-based Medicine (Sativex) in the Treatment of Pain Caused by Rheumatoid Arthritis


  • The Nonpsychoactive Cannabis Constituent Cannabidiol Is an Oral Anti-arthritic Therapeutic in Murine Collagen-induced Arthritis


  • Involvement of the Endocannabinoid System in Osteoarthritis Pain


  • Attenuation of Early Phase Inflammation by Cannabidiol Prevents Pain and Nerve Damage in Rat Osteoarthritis


  • Cannabidiol Lowers Incidence of Diabetes in Non-obese Diabetic Mice


  • Neuroprotective and Blood-retinal Barrier-preserving Effects of Cannabidiol in Experimental Diabetes


  • Cannabinoids Alter Endothelial Function in the Zucker Rat Model of Type 2 Diabetes


  • Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice


  • Activation of the Peripheral Endocannabinoid System in Human Obesity


  • The Endocannabinoid System and Plant-derived Cannabinoids in Diabetes and Diabetic Complications


  • Cannabidiol Protects Retinal Neurons by Preserving Glutamine Synthetase Activity in Diabetes


  • Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and β-Pancreatic Cells and in Obesity and Hyperglycemia


  • Endocannabinoids and the Control of Energy Homeostasis


  • Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy


  • Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes


  • Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study


  • Biochemical and Immunohistochemical Changes in Delta-9-tetrahydrocannabinol-treated Type 2 Diabetic Rats


  • Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy


  • Diabetic Retinopathy: Role of Inflammation and Potential Therapies for Anti-Inflammation


  • The Endocannabinoid System in Obesity and Type 2 Diabetes


  • Cannabinoid-mediated Modulation of Neuropathic Pain and Microglial Accumulation in a Model of Murine Type I Diabetic Peripheral Neuropathic Pain


  • The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults

  • Cannabidiol: Antiepileptic Drug Comparisons and Interactions in Experimentally Induced Seizures in Rats


  • Report of a Parent Survey of Cannabidiol-enriched Cannabis Use in Pediatric Treatment-resistant Epilepsy


  • The Role of Potassium Bk Channels in Anticonvulsant Effect of Cannabidiol in Pentylenetetrazole and Maximal Electroshock Models of Seizure in Mice


  • Cannabidiol Exerts Anti-convulsant Effects in Animal Models of Temporal Lobe and Partial Seizures


  • Cannabidiol Displays Anti-epileptiform and Antiseizure Properties in Vitro and in Vivo


  • Report of a Parent Survey of Cannabidiol-enriched Cannabis Use in Pediatric Treatment-resistant Epilepsy


  • Cannabis, Cannabidiol, and Epilepsy: from Receptors to Clinical Response


  • Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability


  • Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients


  • Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy?


  • Therapeutic Effects of Cannabinoids in Animal Models of Seizures, Epilepsy, Epileptogenesis, and Epilepsy-related Neuroprotection


  • Pharmacology of Cannabinoids in the Treatment of Epilepsy


  • Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure


  • The Cannabinoids as Potential Antiepileptics


  • Hypnotic and Antiepileptic Effects of Cannabidiol


  • Cannabidiol Exerts Anti-convulsant Effects in Animal Models of Temporal Lobe and Partial Seizures


  • Cannabidivarin (cbdv) Suppresses Pentylenetetrazole (ptz)-induced Increases in Epilepsy-related Gene Expression


  • Seizing an Opportunity for the Endocannabinoid System


  • Endocannabinoid System Protects Against Cryptogenic Seizures


  • Cannabidiol, a Non-psychotropic Component of Cannabis, Attenuates Vomiting and Nausea-like Behaviour Via Indirect Agonism of 5-HT(1A) Somatodendritic Autoreceptors in the Dorsal Raphe Nucleus


  • Regulation of Nausea and Vomiting by Cannabinoids


  • The Effects of Cannabidiol and Tetrahydrocannabinol on Motion-induced Emesis in Suncus Murinus


  • Regulation of Nausea and Vomiting by Cannabinoids and the Endocannabinoid System


  • Preliminary Efficacy and Safety of an Oromucosal Standardized Cannabis Extract in Chemotherapy-induced Nausea and Vomiting


  • Suppression of Lithium Chloride-induced Conditioned Gaping (a Model of Nausea-induced Behaviour) in Rats (using the Taste Reactivity Test) With Metoclopramide Is Enhanced by Cannabidiolic Acid


  • The Prevalence and Incidence of Medicinal Cannabis on Prescription in the Netherlands


  • Interaction Between Non-psychotropic Cannabinoids in Marihuana: Effect of Cannabigerol (CBG) on the Anti-nausea or Anti-emetic Effects of Cannabidiol (CBD) in Rats and Shrews


  • Cannabidiol, a Non-psychoactive Component of Cannabis and Its Synthetic Dimethylheptyl Homolog Suppress Nausea in an Experimental Model With Rats


  • Effect of Combined Oral Doses of Δ(9)-tetrahydrocannabinol (THC) and Cannabidiolic Acid (CBDA) on Acute and Anticipatory Nausea in Rat Models


  • Cannabidiolic Acid Prevents Vomiting in Suncus Murinus and Nausea-induced Behaviour in Rats by Enhancing 5-HT1A Receptor Activation

  • A Double-blind, Randomized, Placebo-controlled, Parallel-group Study of THC/CBD Oromucosal Spray in Combination With the Existing Treatment Regimen, in the Relief of Central Neuropathic Pain in Patients With Multiple Sclerosis


  • Cannabinoids in the Management of Difficult to Treat Pain


  • An Open-label Extension Study to Investigate the Long-term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal Thc Spray in Patients With Terminal Cancer-related Pain Refractory to Strong Opioid Analgesics


  • Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes


  • Pain Relief with Cannabinoids: the Importance of Endocannabinoids and Cannabinoids for Therapy


  • Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable Cancer-related Pain


  • Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats


  • Cannabidiol – Delta9-Tetrahydrocannabinol Interactions on Acute Pain and Locomotor Activity


  • Non-psychoactive Cannabinoids Modulate the Descending Pathway of Antinociception in Anaesthetized Rats Through Several Mechanisms of Action


  • Cannabinoids Suppress Inflammatory and Neuropathic Pain by Targeting Α3 Glycine Receptors


  • Meta-analysis of Cannabis Based Treatments for Neuropathic and Multiple Sclerosis-related Pain


  • Sativex: Clinical Efficacy and Tolerability in the Treatment of Symptoms of Multiple Sclerosis and Neuropathic Pain


  • Cannabinoids for Neuropathic Pain


  • Neuropathic Orofacial Pain: Cannabinoids as a Therapeutic Avenue


  • Oromucosal Delta9-tetrahydrocannabinol/cannabidiol for Neuropathic Pain Associated With Multiple Sclerosis: an Uncontrolled, Open-label, 2-year Extension Trial


  • The Non-psychoactive Cannabis Constituent Cannabidiol Is an Orally Effective Therapeutic Agent in Rat Chronic Inflammatory and Neuropathic Pain


  • Vanilloid TRPV1 Receptor Mediates The Antihyperalgesic Effect Of The Nonpsychoactive Cannabinoid, Cannabidiol, In A Rat Model Of Acute Inflammation


  • Cannabidiol Inhibits Paclitaxel-induced Neuropathic Pain Through 5-HT1A) Receptors Without Diminishing Nervous System Function or Chemotherapy Efficacy


  • Sativex Successfully Treats Neuropathic Pain Characterised by Allodynia: a Randomised, Double-blind, Placebo-controlled Clinical Trial


  • Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex, a Cannabis-based Medicine

bottom of page